MRD Analysis in Chronic Lymphocytic Leukemia

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

This Program's Key Topics

What Is MRD in Hematologic Malignancies?

Why Measure MRD in CLL?

When Could We Measure MRD?

PCR for the Detection of MRD

Flow Cytometry for the Detection of MRD

MRD Analysis in CLL Using Flow Cytometry

Next-Generation Sequencing

U-MRD Prediction of PFS Is Largely Independent of Treatment

MRD Level Functions as a Continuous Variable

U-MRD is Prognostic Independent of Clinical Response After Chemoimmunotherapy

Disease Biology Still Matters Even When You Know MRD Status

Multivariable Analysis From CLL8 and CLL10 PFS Data

Can We Use MRD as an Endpoint in Clinical Trials?

What Do We Do About Post-Treatment MRD Positivity?

What About Interim MRD Analysis?

Patients With >1% MRD After C3 FCR Have Poor Outcomes

MRD in the Setting of Novel Therapies

MURANO: Superior PFS Benefit With Fixed-Duration VenR at 3 Years

PB U-MRD Rates Are Higher With VenR Than BR at End of Treatment

U-MRD Status at End of Therapy Is Highly Predictive of Prolonged PFS

MRD Re-Emergence After FCR Precedes Clinical Progression

MRD-Directed Therapy With Venetoclax

MRD Monitoring Post-AlloSCT CLL3X Study

The Future of MRD Analysis in CLL

Abbreviations

Abbreviations (cont)